Entero Therapeutics, Inc.
ENTO
$1.90
-$0.15-7.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 628.20K | 805.60K | 1.28M | 1.69M | 3.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 638.90K | 821.40K | 1.20M | 1.89M | 3.43M |
| Operating Income | -638.90K | -821.40K | -1.20M | -1.89M | -3.43M |
| Income Before Tax | -674.90K | -948.10K | -1.19M | -1.90M | -3.43M |
| Income Tax Expenses | -- | -- | -- | -- | 4.26M |
| Earnings from Continuing Operations | -674.90K | -948.10K | -11.80M | -1.90M | -7.69M |
| Earnings from Discontinued Operations | -323.30K | -311.50K | -439.50K | -685.70K | -1.12M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -998.30K | -1.26M | -12.24M | -2.58M | -8.81M |
| EBIT | -638.90K | -821.40K | -1.20M | -1.89M | -3.43M |
| EBITDA | -635.20K | -817.70K | -1.24M | -1.89M | -3.39M |
| EPS Basic | -0.68 | -0.84 | -9.70 | -1.76 | -11.57 |
| Normalized Basic EPS | -0.27 | -0.33 | 0.90 | -0.78 | -2.80 |
| EPS Diluted | -0.68 | -0.99 | -9.70 | -1.76 | -11.57 |
| Normalized Diluted EPS | -0.27 | -0.33 | 0.90 | -0.78 | -2.80 |
| Average Basic Shares Outstanding | 1.59M | 1.59M | 1.15M | 1.52M | 764.70K |
| Average Diluted Shares Outstanding | 1.59M | 1.59M | 1.15M | 1.52M | 764.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |